Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07830888 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mitral Valve Prolapse Arrhythmic Risk

Study acronym: MVP-Risk
StatusRecruiting
PhaseNot specified
Started2026-08-07
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Oslo University Hospital

Amendment history

2026-09-30
Primary endpoint(s) modified1 entry, revised
WasSevere Ventricular Arrhythmias
NowOccurence and Number of Severe Ventricular Arrhythmias in participants
Mitral valve prolapse (MVP) is common with a 2-3 % prevalence in the general association and generally associated with a favorable prognosis. However, a subgroup of MVP patients, known as arrhythmic mitral valve prolapse (AMVP) has an increased burden of severe ventricular arrhythmias and risk of sudden cardiac death. Identifying high risk patients who may benefit of potential implantable cardioverter-defibrillator (ICD) implantation is therefore critically important. Risk stratification in AMVP is still challenging, and the ability to estimate arrhythmic risk at the individual level is limited.
Trial Details
NCT Number NCT07830888
Lead Sponsor Oslo University Hospital
Conditions Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest
Enrollment 500 participants
Start Date 2026-08-07
Primary Completion 2035-09 (estimated)
Study Completion 2035-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-29